Zobrazeno 1 - 10
of 42
pro vyhledávání: '"J P, Neijt"'
Autor:
P. A. v. d. Wouw, H. H. v. Rooy, R. W. Koster, A. J. Porsius, R. G. A. van Wayjen, A. van den Ende, R. G. L. van Tol, T. R. MacGregor, J. Mooy, B. c. Arends, R. Böhm, J. v. Kemenade, M. v. Baak, K. H. Rahn, P. P. Koopmans, Th. Thien, C. M. C. Thomas, F. W. J. Gribnau, J. G. Timmer, A. Vyth, W. Th. Kok, J. M. B. V. de Jong, W. A. den Hartog Jager, J. W. P. M. Overdiek, F. H. H. M. Merkus, M. A. van Bàak, D. de Ryckc, O. Teirlynck, M. G. Bogaert, P. Smits, A. van 't Laar, B. A. M. van Schaik, G. G. Geyskes, J. C. Roos, E. J. Dorhout Mees, G. J. Navis, P. E. de Jong, A. J. M. Donker, G. K. v. d. Hem, D. de Zeeuw, A. H. van den Meiracker, A. J. Man in't Veld, C. J. R. Ritsema, null van Eck, F. H. M. Derkx, M. A. D. H. Schalekamp, J. H. M. Berkelmans, H. Wollersheim, A. C. Dullemond-Westland, J. P. Neijt, J. W. R. Nortier, J. M. A. Sitsen, P. Vermeij, P. M. Edelbroek, M. D. Ferrari, O. J. S. Buruma, F. A. de Wolff, F. Elferink, W. J. F. van der Vijgh, I. Klein, W. W. ten Bokkel Huinink, H. M. Pinedo, M. Raghoebar, H. L. G. M. Tiemessen, P. L. C. M. van Kiel, W. B. van den Berg, C. A. M. van Ginneken
Publikováno v:
Pharmacy World & Science. 15:3A-9A
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1136:113-118
Evidence is presented that the nitroxide free radical, TEMPO, at concentrations commonly used to prevent oxidative damage, increases the intracellular hydrogen peroxide concentration. To investigate the origin of this increased hydrogen peroxide conc
Autor:
A. C. E. van der Minnen, C. J. A. van Echteld, J. J. W. Lagendijk, P. E. Sijens, W. H. de Jong, D. Seijkens, J. P. Neijt, R. H. van Rijssel, G. de Groot
Publikováno v:
NMR in Biomedicine. 3:124-131
The response of tumours to treatment with the cytostatic drugs cisplatin (CDDP) or doxorubicin (DXR) was followed in vivo by 31P NMR spectroscopy. A CDDP-sensitive parent line (IgM-I) and a CDDP-resistant subline (IgM/CDDP) of the IgM-immunocytoma gr
Autor:
J S, Berek, K, Bertelsen, A, du Bois, M F, Brady, J, Carmichael, E A, Eisenhauer, M, Gore, S, Grenman, T C, Hamilton, S W, Hansen, P G, Harper, G, Horvath, S B, Kaye, H J, Lück, B, Lund, W P, McGuire, J P, Neijt, R F, Ozols, M K, Parmar, M J, Piccart-Gebhart, R, van Rijswijk, P, Rosenberg, G J, Rustin, C, Sessa, J T, Thigpen, C, Tropé, M K, Tuxen, I, Vergote, J B, Vermorken, P H, Willemse
Publikováno v:
Gynecologie, obstetriquefertilite. 28(7-8)
Publikováno v:
Studies in health technology and informatics. 68
A diagnostic decision support system (DSS) in medicine is an expert system that aids the physician in the determination of the diagnosis based on findings and test results. The DSS can be divided into 2 different types of components: the knowledge co
Autor:
J P, Neijt
Publikováno v:
Nederlands tijdschrift voor geneeskunde. 143(44)
Shortly after treatment with the cytostatic combination of cisplatin and paclitaxel was generally accepted as the standard therapy for patients with epithelial ovarian carcinoma, many have come to regard the combination of carboplatin and paclitaxel
Autor:
J S, Berek, K, Bertelsen, A, du Bois, M F, Brady, J, Carmichael, E A, Eisenhauer, M, Gore, S, Grenman, T C, Hamilton, S W, Hansen, P G, Harper, G, Horvath, S B, Kaye, H J, Lück, B, Lund, W P, McGuire, J P, Neijt, R F, Ozols, M K, Parmar, M J, Piccart-Gebhart, R, van Rijswijk, P, Rosenberg, G J, Rustin, C, Sessa, P H, Willemse
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 10
During an international workshop held in September 1998, a group of specialists in the field of ovarian cancer reached consensus on a number of issues with implications for standard practice and for research of advanced epithelial ovarian cancer.Five
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 10
Cisplatin 75 mg/m2 plus paclitaxel 135 mg/m2 administered over 24 hours have been established as the standard treatment for advanced ovarian cancer. This schedule can not be administered in an outpatient setting. A European-Canadian trial confirmed t
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 10
There are only rare circumstances where knowledge of a patient's prognostic features appropriately guides therapy. The last few years a plethora of studies have been published which attempt to refine our understanding of determinants of prognosis in
Autor:
J P, Neijt, A, du Bois
Publikováno v:
Seminars in oncology. 26(1 Suppl 2)
In 1996, the combination of cisplatin 75 mg/m2 plus 24-hour infusion of 135 mg/m2 paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) was proved to prolong survival in comparison with cyclophosphamide/cisplatin in women with advanced ovar